EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanomedicines Targeting Metabolic Pathways in the Tumor Microenvironment: Future Perspectives and the Role of AI

Shuai Fan iD, Wenyu Wang, Wenbo Che, Yicheng Xu, Chuan Jin, Lei Dong iD, Qin Xia iD

Metabolites · 13.03.2025 · 15 (3) · 201

DOI: 10.3390/metabo15030201 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 13.03.2025. Verfasst von Shuai Fan und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Medicine and Biological Diagnosis and Treatment (Ministry of Industry and Information Technology), Aerospace Center…. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 476 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor cells engage in continuous self-replication by utilizing a large number of resources and capabilities, typically within an aberrant metabolic regulatory network to meet their own demands. This metabolic dysregulation leads to the formation of the tumor microenvironment (TME) in most solid tumors. Nanomedicines, due to their unique physicochemical properties, can achieve passive targeting in certain solid tumors through the enhanced permeability and retention (EPR) effect, or active targeting through deliberate design optimization, resulting in accumulation within the TME. The use of nanomedicines to target critical metabolic pathways in tumors holds significant promise. However, the design of nanomedicines requires the careful selection of relevant drugs and materials, taking into account multiple factors. The traditional trial-and-error process is relatively inefficient. Artificial intelligence (AI) can integrate big data to evaluate the accumulation and delivery efficiency of nanomedicines, thereby assisting in the design of nanodrugs.

Methods

We have conducted a detailed review of key papers from databases, such as ScienceDirect, Scopus, Wiley, Web of Science, and PubMed, focusing on tumor metabolic reprogramming, the mechanisms of action of nanomedicines, the development of nanomedicines targeting tumor metabolism, and the application of AI in empowering nanomedicines. We have integrated the relevant content to present the current status of research on nanomedicines targeting tumor metabolism and potential future directions in this field.

Results

Nanomedicines possess excellent TME targeting properties, which can be utilized to disrupt key metabolic pathways in tumor cells, including glycolysis, lipid metabolism, amino acid metabolism, and nucleotide metabolism. This disruption leads to the selective killing of tumor cells and disturbance of the TME. Extensive research has demonstrated that AI-driven methodologies have revolutionized nanomedicine development, while concurrently enabling the precise identification of critical molecular regulators involved in oncogenic metabolic reprogramming pathways, thereby catalyzing transformative innovations in targeted cancer therapeutics.

Conclusions

The development of nanomedicines targeting tumor metabolic pathways holds great promise. Additionally, AI will accelerate the discovery of metabolism-related targets, empower the design and optimization of nanomedicines, and help minimize their toxicity, thereby providing a new paradigm for future nanomedicine development.

Schlagwörter

Stichwörter der Autor:innen

TMEartificial intelligencemetabolismnanomedicinetumor

Autor:innen und Institutionen

  • State Key Laboratory of Molecular Medicine and Biological Diagnosis and Treatment (Ministry of Industry and Information Technology), Aerospace Center Hospital, School of Life Science, Beijing Institute of Technology, Be…

ORCID-Profile: Shuai Fan, Lei Dong, Qin Xia

Förderung

  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Shandong Provincial Natural Science Foundation
  • Beijing Municipal Natural Science Foundation
  • 2023 En San Frontier Innovation Fund Third Batch of Funded Projects-919

Zitieren

APA

Fan, S., Wang, W., Che, W., Xu, Y., Jin, C., Dong, L., & Xia, Q. (2025). Nanomedicines Targeting Metabolic Pathways in the Tumor Microenvironment: Future Perspectives and the Role of AI. Metabolites, 15(3), 201. https://doi.org/10.3390/metabo15030201

Vancouver

Fan S, Wang W, Che W, Xu Y, Jin C, Dong L, et al. Nanomedicines Targeting Metabolic Pathways in the Tumor Microenvironment: Future Perspectives and the Role of AI. Metabolites. 2025;15(3):201. doi:10.3390/metabo15030201

BibTeX
@article{Fan2025,
  author = {Fan, Shuai and Wang, Wenyu and Che, Wenbo and Xu, Yicheng and Jin, Chuan and Dong, Lei and Xia, Qin},
  title = {Nanomedicines Targeting Metabolic Pathways in the Tumor Microenvironment: Future Perspectives and the Role of AI},
  journal = {Metabolites},
  year = {2025},
  volume = {15},
  number = {3},
  pages = {201},
  doi = {10.3390/metabo15030201}
}
Kostenlos starten →